|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis显示文摘 | B. Bournet A. Souque P. Senesse E. Assenat M. Barthet N. Lesavre A. Aubert D. O’Toole P. Hammel P. Levy P. Ruszniewski M. Bouisson J. Escourrou P. Cordelier L. Buscail | 2009 | Endoscopy2009，，06： | 2 |
| 2 | Nutritional support during oncologic treatment of patients with gastrointestinal cancer:who could benefit?显示文摘 | SENESSE P ASSENAT E SCHNEIDER S | 2008 | Cancer Treat Rev2008，34，6： | 1 |
| 3 | Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit显示文摘 | Senesse P Assenat E Schneider S | 2008 | Cancer Treat Rev2008，34，6： | 1 |
| 4 | Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit显示文摘 | Senesse P Assenat E Schneider S | 2008 | Cancer Treat Rev2008，34，6： | 1 |
| 5 | Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples显示文摘 | B. Bournet A. Pointreau A. Souque N. Oumouhou F. Muscari B. Lepage P. Senesse M. Barthet N. Lesavre P. Hammel P. Levy P. Ruszniewski P. Cordelier L. Buscail | 2012 | Pancreatology2012，，1： | 1 |
| 6 | Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit 显示文摘 | Senesse P Assenat E Schneider S | 2008 | Cancer Treat Rev2008，34，6： | 1 |
| 7 | Tobacco use and associations of beta-carotene and vitamin intakes with colorectal adenoma risk显示文摘 | Touvier M Kesse E | 2005 | J Nutr2005，135，10： | 1 |
| 8 | Foods as risk factom for colorectal cancer:a case-control study in Burgundy (France)显示文摘 | Boutron-Ruauh MC Senesse P Faivre J | 1999 | Eur J Cancer Prey1999，8，3： | 1 |
| 9 | Nutritional support during oncologic treatment of patients with gastrointestinal cancer:Who could benefit ?显示文摘 | Senesse P Assenat E Schneider S | 2008 | Cancer Treat Rev2008，3，4： | 1 |
| 10 | Foods as risk factors for colorectal cancer:a case-control study in Burgundy(France)显示文摘 | BOUTRON-RUAULT M C SENESSE P FAIVRE J | 1999 | European Journal of Cancer Prevention1999，8，： | 1 |
| 11 | Clinical impact of lymph node status in rectal cancer显示文摘 | P.E. Colombo N. Patani F. Bibeau E. Assenat M.M. Bertrand P. Senesse P. Rouanet | 2011 | Surgical Oncology2011，，4： | 1 |
| 12 | Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis 显示文摘 | Bournet B Souque A Senesse P | 2009 | Endoscopy2009，41，5： | 1 |
| 13 | Endoscopic ultrasoundguided fine-needle aspiration biopsy coupled with K-ras mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis显示文摘 | Bournet B Souque A Senesse P | 2009 | Endoscopy2009，41，： | 1 |
| 14 | Cyclin D1 Gene G870A Polymorphism Predicts Response to Neoadjuvant Radiotherapy and Prognosis in Rectal Cancer显示文摘 | Alexandre Ho-Pun-Cheung Eric Assenat Simon Thezenas Frédéric Bibeau Philippe Rouanet David Azria Dominic Cellier Jean Grenier Marc Ychou Pierre Senesse Evelyne Lopez-Crapez | 2007 | International Journal of Radiation Oncology, Biology, Physics2007，，4： | 1 |
| 15 | Diagnostic criteria for the classification of cancer-associated weight loss 显示文摘 | Martin L Senesse P Gioulhasanis I | 2015 | J Clin Oncol2015，33，1： | 1 |
| 16 | Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer显示文摘AIM:To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastatic pancreatic cancer [(frequency,response,outcome,course of carbohydrate antigen 19-9 (CA 19-9)].METHODS:This retrospective study included all patients with advanced or metastatic pancreatic cancer (adenocarcinoma or carcinoma) treated with secondline chemotherapy in our center between 2000 and 2008.All patients received first-line chemotherapy with gemcitabine,and prior surgery or radiotherapy was permitted.We analyzed each chemotherapy protocol for second-line treatment,the number of cycles and the type of combination used.The primary endpoint was overall survival.Secondary endpoints included progression-free survival,response rate,grade 3-4 toxicity,dosage modifications and CA 19-9 course.RESULTS:A total of eighty patients (38%) underwenta second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabine-based regimen.Median number of cycles was 4 (range:1-12) and the median duration of treatment was 2.6 mo (range:0.3-7.4).The overall disease control rate was 40.0%.The median overall survival and progression-free survival from the start of second-line therapy were 5.8 (95% CI:4.1-6.6) and 3.4 mo (95% CI:2.4-4.2),respectively.Toxicity was generally acceptable.Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo (95% CI:4.5-11.6) vs 5.2 mo (95% CI:4.0-6.4) for others (P=0.008).CONCLUSION:A large proportion of patients could benefit from second-line therapy,and CA 19-9 allows efficient treatment monitoring both in first and secondline chemotherapy. | Romain Altwegg Marc Ychou Vanessa Guillaumon Simon Thezenas Pierre Senesse Nicolas Flori Thibault Mazard Ludovic Caillo Stéphanie Faure Emmanuelle Samalin Eric Assenat | 2012 | World Journal of Gastroenterology2012，18，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员